English

ImmunoCellular Therapeutics, Ltd.

EDGAR

IMUC Report (type unavailable) · filed 2022-06-24

86 filing records in this dataset, filed from 1999-11-24 to 2022-06-24. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2018 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-2.17 million USD

2018 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -3777265 USD Source
Operating Cash Flow: -1603268 USD Source

Cash and cash equivalents: 2.85 million USD 2018-06-30 Source
Exact value

2852605 USD
Long-term debt including current maturities: 0 USD 2017-12-31 Source
Exact value

0 USD
Shares outstanding: 41.9 million shares 2018-06-30 Source
Exact value

41913256 shares

Reported share-count change

1,080.13% · 38.4 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

3551575 shares · 2017-06-30· Source
41913256 shares · 2018-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-06-24.

Financial data available through: 2017-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2017-12-31
Operating income: 8 of 11 periods available· newest 2017-12-31
Net income: 11 of 11 periods available· newest 2017-12-31
Operating cash flow: 8 of 11 periods available· newest 2017-12-31
Capital expenditure: 8 of 11 periods available· newest 2017-12-31
Total assets: 8 of 11 periods available· newest 2017-12-31
Total liabilities: 4 of 11 periods available· newest 2017-12-31
Current assets: 8 of 11 periods available· newest 2017-12-31
Current liabilities: 8 of 11 periods available· newest 2017-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2017-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2017-12-31
Shares outstanding: 7 of 11 periods available· newest 2017-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2016-01-01 – 2016-12-31
Current period

USD 0

2017-01-01 – 2017-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
0 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ImmunoCellular Therapeutics, Ltd. · 2017-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#243130 Filing: 000082241118000004 Input fundies:Revenue: 0 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#242995 Filing: 000082241118000004
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 7.77 million

Prior period

−USD 22.09 million

2016-01-01 – 2016-12-31
Current period

−USD 14.31 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-14312007 − -22085702 = 7773695 USD

-22085702 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-14312007 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ImmunoCellular Therapeutics, Ltd. · 2017-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Year-over-year change in Net income: 7773695 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -14312007 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#221311 Filing: 000082241118000004 Input fundies:NetIncome: -22085702 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#220936 Filing: 000082241118000004
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 3.19 million

Prior period

−USD 19.86 million

2016-01-01 – 2016-12-31
Current period

−USD 16.67 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-16671777 − -19864442 = 3192665 USD

-19864442 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-16671777 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ImmunoCellular Therapeutics, Ltd. · 2017-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Year-over-year change in Operating cash flow: 3192665 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -16671777 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#220350 Filing: 000082241118000004 Input fundies:OperatingCashFlow: -19864442 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#220139 Filing: 000082241118000004
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%

Prior period

USD 4,015

2016-01-01 – 2016-12-31
Current period

USD 0

2017-01-01 – 2017-12-31

Exact inputs and evidence

0 − 4015 = -4015 USD

4015 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
0 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ImmunoCellular Therapeutics, Ltd. · 2017-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Year-over-year change in Capital expenditure: -4015 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#224959 Filing: 000082241118000004 Input fundies:CapitalExpenditure: 4015 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#224753 Filing: 000082241118000004
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2017 2017-01-01 – 2017-12-31

Revenue USD 0
Operating costs Derived USD 21.15 million
Operating income −USD 21.15 million
Tax, interest and other Derived −USD 6.84 million
Net income −USD 14.31 million

Cash

Operating cash flow −USD 16.67 million
Capital expenditure USD 0
Free cash flow Derived −USD 16.67 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2010 Not shown: operating income or net income is not reported.
2011 Not shown: operating income or net income is not reported.
2012 Not shown: operating income or net income is not reported.
2013 Not shown: operating income or net income is not reported.
2014 Not shown: operating income or net income is not reported.
2015 Not shown: operating income or net income is not reported.
2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2010 2010-01-01 – 2010-12-31	5136009 Derived	-5136009	1014133 Derived	-6150142	-4264132 Derived	Source 2010-01-01 – 2010-12-31: 0 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: -5136009 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: -6150142 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: -4253560 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 10572 USD Inspect Capital Expenditure Open source
2011 2011-01-01 – 2011-12-31	8625502 Derived	-8625502	-2905599 Derived	-5719903	-6468134 Derived	Source 2011-01-01 – 2011-12-31: 0 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: -8625502 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: -5719903 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: -6383742 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 84392 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	11826531 Derived	-11826531	2668608 Derived	-14495139	-12389841 Derived	Source 2012-01-01 – 2012-12-31: 0 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -11826531 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -14495139 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -12380013 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 9828 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	9460319 Derived	-9460319	-659756 Derived	-8800563	-8831589 Derived	Source 2013-01-01 – 2013-12-31: 0 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -9460319 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -8800563 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -8787217 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 44372 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	9858541 Derived	-9858541	-481008 Derived	-9377533	-9965777 Derived	Source 2014-01-01 – 2014-12-31: 0 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -9858541 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -9377533 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -9936802 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 28975 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	15513091 Derived	-15513091	-2722277 Derived	-12790814	-19209151 Derived	Source 2015-01-01 – 2015-12-31: 0 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -15513091 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -12790814 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -19039401 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 169750 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	24112125 Derived	-24112125	-2026423 Derived	-22085702	-19868457 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -24112125 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -22085702 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -19864442 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 4015 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	21153444 Derived	-21153444	-6841437 Derived	-14312007	-16671777 Derived	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -21153444 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -14312007 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -16671777 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 0 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2017

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20102010-12-31	Revenue	Revenue: 0 Open source
20112011-12-31	Revenue	Revenue: 0 Open source
20122012-12-31	Revenue	Revenue: 0 Open source
20132013-12-31	Revenue	Revenue: 0 Open source
20142014-12-31	Revenue	Revenue: 0 Open source
20152015-12-31	Revenue	Revenue: 0 Open source
20162016-12-31	Revenue	Revenue: 0 Open source
20172017-12-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20112011-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20122012-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20132013-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20142014-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20152015-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Operating margin	Not reported	Operating Income: -5136009 Open source Revenue: 0 Open source
20112011-12-31	Operating margin	Not reported	Operating Income: -8625502 Open source Revenue: 0 Open source
20122012-12-31	Operating margin	Not reported	Operating Income: -11826531 Open source Revenue: 0 Open source
20132013-12-31	Operating margin	Not reported	Operating Income: -9460319 Open source Revenue: 0 Open source
20142014-12-31	Operating margin	Not reported	Operating Income: -9858541 Open source Revenue: 0 Open source
20152015-12-31	Operating margin	Not reported	Operating Income: -15513091 Open source Revenue: 0 Open source
20162016-12-31	Operating margin	Not reported	Operating Income: -24112125 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -21153444 Open source Revenue: 0 Open source
20102010-12-31	Net margin	Not reported	Net Income: -6150142 Open source Revenue: 0 Open source
20112011-12-31	Net margin	Not reported	Net Income: -5719903 Open source Revenue: 0 Open source
20122012-12-31	Net margin	Not reported	Net Income: -14495139 Open source Revenue: 0 Open source
20132013-12-31	Net margin	Not reported	Net Income: -8800563 Open source Revenue: 0 Open source
20142014-12-31	Net margin	Not reported	Net Income: -9377533 Open source Revenue: 0 Open source
20152015-12-31	Net margin	Not reported	Net Income: -12790814 Open source Revenue: 0 Open source
20162016-12-31	Net margin	Not reported	Net Income: -22085702 Open source Revenue: 0 Open source
20172017-12-31	Net margin	Not reported	Net Income: -14312007 Open source Revenue: 0 Open source
20102010-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -4253560 Open source Capital Expenditure: 10572 Open source
20112011-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -6383742 Open source Capital Expenditure: 84392 Open source
20122012-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -12380013 Open source Capital Expenditure: 9828 Open source
20132013-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -8787217 Open source Capital Expenditure: 44372 Open source
20142014-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -9936802 Open source Capital Expenditure: 28975 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -19039401 Open source Capital Expenditure: 169750 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -19864442 Open source Capital Expenditure: 4015 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -16671777 Open source Capital Expenditure: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -16.7M 2017

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Operating cash flow	-4253560	Operating Cash Flow: -4253560 Open source
20112011-12-31	Operating cash flow	-6383742	Operating Cash Flow: -6383742 Open source
20122012-12-31	Operating cash flow	-12380013	Operating Cash Flow: -12380013 Open source
20132013-12-31	Operating cash flow	-8787217	Operating Cash Flow: -8787217 Open source
20142014-12-31	Operating cash flow	-9936802	Operating Cash Flow: -9936802 Open source
20152015-12-31	Operating cash flow	-19039401	Operating Cash Flow: -19039401 Open source
20162016-12-31	Operating cash flow	-19864442	Operating Cash Flow: -19864442 Open source
20172017-12-31	Operating cash flow	-16671777	Operating Cash Flow: -16671777 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -16.7M 2017

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Free cash flow	-4264132	Operating Cash Flow: -4253560 Open source Capital Expenditure: 10572 Open source
20112011-12-31	Free cash flow	-6468134	Operating Cash Flow: -6383742 Open source Capital Expenditure: 84392 Open source
20122012-12-31	Free cash flow	-12389841	Operating Cash Flow: -12380013 Open source Capital Expenditure: 9828 Open source
20132013-12-31	Free cash flow	-8831589	Operating Cash Flow: -8787217 Open source Capital Expenditure: 44372 Open source
20142014-12-31	Free cash flow	-9965777	Operating Cash Flow: -9936802 Open source Capital Expenditure: 28975 Open source
20152015-12-31	Free cash flow	-19209151	Operating Cash Flow: -19039401 Open source Capital Expenditure: 169750 Open source
20162016-12-31	Free cash flow	-19868457	Operating Cash Flow: -19864442 Open source Capital Expenditure: 4015 Open source
20172017-12-31	Free cash flow	-16671777	Operating Cash Flow: -16671777 Open source Capital Expenditure: 0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

33.7% 2017

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2010-12-31	Liabilities / assets	Not reported	No source recorded
2011-12-31	Liabilities / assets	Not reported	Total Assets: 7150757 Open source
2012-12-31	Liabilities / assets	Not reported	Total Assets: 27019201 Open source
2013-12-31	Liabilities / assets	Not reported	Total Assets: 28940677 Open source
20142014-12-31	Liabilities / assets	7.5%	Total Liabilities: 1886918 Open source Total Assets: 25178561 Open source
20152015-12-31	Liabilities / assets	27.8%	Total Liabilities: 8362078 Open source Total Assets: 30082374 Open source
20162016-12-31	Liabilities / assets	63.7%	Total Liabilities: 10758244 Open source Total Assets: 16889990 Open source
20172017-12-31	Liabilities / assets	33.7%	Total Liabilities: 2360754 Open source Total Assets: 7009225 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.97× 2017

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2010-12-31	Current assets / current liabilities	Not reported	No source recorded
20112011-12-31	Current assets / current liabilities	3.83×	Current Assets: 6744454 Open source Current Liabilities: 1761289 Open source
20122012-12-31	Current assets / current liabilities	24.52×	Current Assets: 26931176 Open source Current Liabilities: 1098307 Open source
20132013-12-31	Current assets / current liabilities	20.26×	Current Assets: 28409650 Open source Current Liabilities: 1402273 Open source
20142014-12-31	Current assets / current liabilities	18.96×	Current Assets: 24442169 Open source Current Liabilities: 1289199 Open source
20152015-12-31	Current assets / current liabilities	10.82×	Current Assets: 24560538 Open source Current Liabilities: 2269398 Open source
20162016-12-31	Current assets / current liabilities	4.14×	Current Assets: 13414789 Open source Current Liabilities: 3238943 Open source
20172017-12-31	Current assets / current liabilities	2.97×	Current Assets: 7008657 Open source Current Liabilities: 2360754 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2008 2008-01-01 – 2008-12-31	−USD 3.06 million Exact value Exact value: -3059730 USD 2008-01-01 – 2008-12-31: -3059730 USD Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoCellular Therapeutics, Ltd. · 2008-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Net Income: -3059730 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3059730 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459014002006/imuc-20140331.xml#168180 Filing: 000156459014002006 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Operating cash flow + Capital expenditure is unavailable for this period.
2009 2009-01-01 – 2009-12-31	−USD 2.63 million Exact value Exact value: -2626205 USD 2009-01-01 – 2009-12-31: -2626205 USD Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoCellular Therapeutics, Ltd. · 2009-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Net Income: -2626205 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ANetIncome&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2626205 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459014002006/imuc-20140331.xml#174095 Filing: 000156459014002006 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Operating cash flow + Capital expenditure is unavailable for this period.
2010 2010-01-01 – 2010-12-31	−USD 6.15 million Exact value Exact value: -6150142 USD 2010-01-01 – 2010-12-31: -6150142 USD Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoCellular Therapeutics, Ltd. · 2010-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Net Income: -6150142 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6150142 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459014002006/imuc-20140331.xml#188113 Filing: 000156459014002006 The citation records this snapshot. The page link may show a newer release later.	−USD 4.25 million Exact value Exact value: -4253560 USD 2010-01-01 – 2010-12-31: -4253560 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoCellular Therapeutics, Ltd. · 2010-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Operating Cash Flow: -4253560 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4253560 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000119312513101316/imuc-20121231.xml#694406 Filing: 000119312513101316 The citation records this snapshot. The page link may show a newer release later.	USD 10,572 Exact value Exact value: 10572 USD 2010-01-01 – 2010-12-31: 10572 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoCellular Therapeutics, Ltd. · 2010-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Capital Expenditure: 10572 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10572 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000119312513101316/imuc-20121231.xml#707791 Filing: 000119312513101316 The citation records this snapshot. The page link may show a newer release later.	−USD 4.26 million Calculation and evidence -4253560 − 10572 USD Exact free cash flow: -4264132 USD 2010-01-01 – 2010-12-31: -4253560 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 10572 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoCellular Therapeutics, Ltd. · 2010-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Free cash flow: -4264132 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4253560 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000119312513101316/imuc-20121231.xml#694406 Filing: 000119312513101316 Input fundies:CapitalExpenditure: 10572 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000119312513101316/imuc-20121231.xml#707791 Filing: 000119312513101316 The citation records this snapshot. The page link may show a newer release later.
2011 2011-01-01 – 2011-12-31	−USD 5.72 million Exact value Exact value: -5719903 USD 2011-01-01 – 2011-12-31: -5719903 USD Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoCellular Therapeutics, Ltd. · 2011-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Net Income: -5719903 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5719903 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459014002006/imuc-20140331.xml#194878 Filing: 000156459014002006 The citation records this snapshot. The page link may show a newer release later.	−USD 6.38 million Exact value Exact value: -6383742 USD 2011-01-01 – 2011-12-31: -6383742 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoCellular Therapeutics, Ltd. · 2011-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Operating Cash Flow: -6383742 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6383742 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459014000771/imuc-20131231.xml#359088 Filing: 000156459014000771 The citation records this snapshot. The page link may show a newer release later.	USD 84,392 Exact value Exact value: 84392 USD 2011-01-01 – 2011-12-31: 84392 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoCellular Therapeutics, Ltd. · 2011-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Capital Expenditure: 84392 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 84392 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459014000771/imuc-20131231.xml#359922 Filing: 000156459014000771 The citation records this snapshot. The page link may show a newer release later.	−USD 6.47 million Calculation and evidence -6383742 − 84392 USD Exact free cash flow: -6468134 USD 2011-01-01 – 2011-12-31: -6383742 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 84392 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoCellular Therapeutics, Ltd. · 2011-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Free cash flow: -6468134 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6383742 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459014000771/imuc-20131231.xml#359088 Filing: 000156459014000771 Input fundies:CapitalExpenditure: 84392 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459014000771/imuc-20131231.xml#359922 Filing: 000156459014000771 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	−USD 14.5 million Exact value Exact value: -14495139 USD 2012-01-01 – 2012-12-31: -14495139 USD Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoCellular Therapeutics, Ltd. · 2012-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Net Income: -14495139 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14495139 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459015001446/imuc-20141231.xml#90937 Filing: 000156459015001446 The citation records this snapshot. The page link may show a newer release later.	−USD 12.38 million Exact value Exact value: -12380013 USD 2012-01-01 – 2012-12-31: -12380013 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoCellular Therapeutics, Ltd. · 2012-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Operating Cash Flow: -12380013 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12380013 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459015001446/imuc-20141231.xml#119478 Filing: 000156459015001446 The citation records this snapshot. The page link may show a newer release later.	USD 9,828 Exact value Exact value: 9828 USD 2012-01-01 – 2012-12-31: 9828 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoCellular Therapeutics, Ltd. · 2012-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Capital Expenditure: 9828 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9828 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459015001446/imuc-20141231.xml#120143 Filing: 000156459015001446 The citation records this snapshot. The page link may show a newer release later.	−USD 12.39 million Calculation and evidence -12380013 − 9828 USD Exact free cash flow: -12389841 USD 2012-01-01 – 2012-12-31: -12380013 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 9828 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoCellular Therapeutics, Ltd. · 2012-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Free cash flow: -12389841 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12380013 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459015001446/imuc-20141231.xml#119478 Filing: 000156459015001446 Input fundies:CapitalExpenditure: 9828 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000156459015001446/imuc-20141231.xml#120143 Filing: 000156459015001446 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 8.8 million Exact value Exact value: -8800563 USD 2013-01-01 – 2013-12-31: -8800563 USD Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoCellular Therapeutics, Ltd. · 2013-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Net Income: -8800563 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8800563 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000162828016013931/imuc-20151231.xml#154275 Filing: 000162828016013931 The citation records this snapshot. The page link may show a newer release later.	−USD 8.79 million Exact value Exact value: -8787217 USD 2013-01-01 – 2013-12-31: -8787217 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoCellular Therapeutics, Ltd. · 2013-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Operating Cash Flow: -8787217 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8787217 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000162828016013931/imuc-20151231.xml#153524 Filing: 000162828016013931 The citation records this snapshot. The page link may show a newer release later.	USD 44,372 Exact value Exact value: 44372 USD 2013-01-01 – 2013-12-31: 44372 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoCellular Therapeutics, Ltd. · 2013-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Capital Expenditure: 44372 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 44372 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000162828016013931/imuc-20151231.xml#157903 Filing: 000162828016013931 The citation records this snapshot. The page link may show a newer release later.	−USD 8.83 million Calculation and evidence -8787217 − 44372 USD Exact free cash flow: -8831589 USD 2013-01-01 – 2013-12-31: -8787217 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 44372 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoCellular Therapeutics, Ltd. · 2013-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Free cash flow: -8831589 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8787217 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000162828016013931/imuc-20151231.xml#153524 Filing: 000162828016013931 Input fundies:CapitalExpenditure: 44372 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000162828016013931/imuc-20151231.xml#157903 Filing: 000162828016013931 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 9.38 million Exact value Exact value: -9377533 USD 2014-01-01 – 2014-12-31: -9377533 USD Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoCellular Therapeutics, Ltd. · 2014-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Net Income: -9377533 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9377533 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000162828017002439/imuc-20161231.xml#146428 Filing: 000162828017002439 The citation records this snapshot. The page link may show a newer release later.	−USD 9.94 million Exact value Exact value: -9936802 USD 2014-01-01 – 2014-12-31: -9936802 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoCellular Therapeutics, Ltd. · 2014-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Operating Cash Flow: -9936802 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9936802 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000162828017002439/imuc-20161231.xml#145676 Filing: 000162828017002439 The citation records this snapshot. The page link may show a newer release later.	USD 28,975 Exact value Exact value: 28975 USD 2014-01-01 – 2014-12-31: 28975 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoCellular Therapeutics, Ltd. · 2014-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Capital Expenditure: 28975 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 28975 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000162828017002439/imuc-20161231.xml#151343 Filing: 000162828017002439 The citation records this snapshot. The page link may show a newer release later.	−USD 9.97 million Calculation and evidence -9936802 − 28975 USD Exact free cash flow: -9965777 USD 2014-01-01 – 2014-12-31: -9936802 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 28975 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoCellular Therapeutics, Ltd. · 2014-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Free cash flow: -9965777 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9936802 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000162828017002439/imuc-20161231.xml#145676 Filing: 000162828017002439 Input fundies:CapitalExpenditure: 28975 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000162828017002439/imuc-20161231.xml#151343 Filing: 000162828017002439 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 12.79 million Exact value Exact value: -12790814 USD 2015-01-01 – 2015-12-31: -12790814 USD Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoCellular Therapeutics, Ltd. · 2015-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Net Income: -12790814 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12790814 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#220561 Filing: 000082241118000004 The citation records this snapshot. The page link may show a newer release later.	−USD 19.04 million Exact value Exact value: -19039401 USD 2015-01-01 – 2015-12-31: -19039401 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoCellular Therapeutics, Ltd. · 2015-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Operating Cash Flow: -19039401 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19039401 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#219928 Filing: 000082241118000004 The citation records this snapshot. The page link may show a newer release later.	USD 169,750 Exact value Exact value: 169750 USD 2015-01-01 – 2015-12-31: 169750 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoCellular Therapeutics, Ltd. · 2015-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Capital Expenditure: 169750 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 169750 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#224545 Filing: 000082241118000004 The citation records this snapshot. The page link may show a newer release later.	−USD 19.21 million Calculation and evidence -19039401 − 169750 USD Exact free cash flow: -19209151 USD 2015-01-01 – 2015-12-31: -19039401 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 169750 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoCellular Therapeutics, Ltd. · 2015-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Free cash flow: -19209151 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19039401 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#219928 Filing: 000082241118000004 Input fundies:CapitalExpenditure: 169750 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#224545 Filing: 000082241118000004 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 22.09 million Exact value Exact value: -22085702 USD 2016-01-01 – 2016-12-31: -22085702 USD Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoCellular Therapeutics, Ltd. · 2016-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Net Income: -22085702 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -22085702 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#220936 Filing: 000082241118000004 The citation records this snapshot. The page link may show a newer release later.	−USD 19.86 million Exact value Exact value: -19864442 USD 2016-01-01 – 2016-12-31: -19864442 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoCellular Therapeutics, Ltd. · 2016-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Operating Cash Flow: -19864442 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19864442 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#220139 Filing: 000082241118000004 The citation records this snapshot. The page link may show a newer release later.	USD 4,015 Exact value Exact value: 4015 USD 2016-01-01 – 2016-12-31: 4015 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoCellular Therapeutics, Ltd. · 2016-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Capital Expenditure: 4015 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4015 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#224753 Filing: 000082241118000004 The citation records this snapshot. The page link may show a newer release later.	−USD 19.87 million Calculation and evidence -19864442 − 4015 USD Exact free cash flow: -19868457 USD 2016-01-01 – 2016-12-31: -19864442 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 4015 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoCellular Therapeutics, Ltd. · 2016-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Free cash flow: -19868457 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19864442 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#220139 Filing: 000082241118000004 Input fundies:CapitalExpenditure: 4015 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#224753 Filing: 000082241118000004 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 14.31 million Exact value Exact value: -14312007 USD 2017-01-01 – 2017-12-31: -14312007 USD Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoCellular Therapeutics, Ltd. · 2017-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Net Income: -14312007 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14312007 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#221311 Filing: 000082241118000004 The citation records this snapshot. The page link may show a newer release later.	−USD 16.67 million Exact value Exact value: -16671777 USD 2017-01-01 – 2017-12-31: -16671777 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoCellular Therapeutics, Ltd. · 2017-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Operating Cash Flow: -16671777 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16671777 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#220350 Filing: 000082241118000004 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2017-01-01 – 2017-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoCellular Therapeutics, Ltd. · 2017-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#224959 Filing: 000082241118000004 The citation records this snapshot. The page link may show a newer release later.	−USD 16.67 million Calculation and evidence -16671777 − 0 USD Exact free cash flow: -16671777 USD 2017-01-01 – 2017-12-31: -16671777 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoCellular Therapeutics, Ltd. · 2017-12-31 ImmunoCellular Therapeutics, Ltd. (edgar:822411) Free cash flow: -16671777 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/822411?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16671777 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#220350 Filing: 000082241118000004 Input fundies:CapitalExpenditure: 0 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/822411/000082241118000004/imuc-20171231.xml#224959 Filing: 000082241118000004 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

86 filings · 2,289 latest values · 2,289 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000822411, 822411, IMUC, edgar:822411

Also known as EOM Pharmaceutical Holdings, Inc., ImmunoCellular Therapeutics, Ltd., Optical Molecular Imaging, Inc, PATCO INDUSTRIES LTD

ImmunoCellular Therapeutics, Ltd.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2017 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation